^
    No biomarker
    Thyroid Gland Papillary Carcinoma
    sorafenib
    Sensitive: A1 - Approval
    No biomarker
    Thyroid Gland Papillary Carcinoma
    lenvatinib
    Sensitive: A1 - Approval
    NTRK2 fusion
    Thyroid Gland Papillary Carcinoma
    larotrectinib
    Sensitive: A2 - Guideline
    No biomarker
    Thyroid Gland Papillary Carcinoma
    denosumab
    Sensitive: A2 - Guideline
    RET fusion
    Thyroid Gland Papillary Carcinoma
    selpercatinib
    Sensitive: A2 - Guideline
    NTRK3 fusion
    Thyroid Gland Papillary Carcinoma
    entrectinib
    Sensitive: A2 - Guideline
    NTRK2 fusion
    Thyroid Gland Papillary Carcinoma
    entrectinib
    Sensitive: A2 - Guideline
    NTRK1 fusion
    Thyroid Gland Papillary Carcinoma
    entrectinib
    Sensitive: A2 - Guideline
    NTRK3 fusion
    Thyroid Gland Papillary Carcinoma
    larotrectinib
    Sensitive: A2 - Guideline
    NTRK1 fusion
    Thyroid Gland Papillary Carcinoma
    larotrectinib
    Sensitive: A2 - Guideline
    TMB-H
    Thyroid Gland Papillary Carcinoma
    pembrolizumab
    Sensitive: A2 - Guideline
    RET fusion
    Thyroid Gland Papillary Carcinoma
    pralsetinib
    Sensitive: A2 - Guideline
    BRAF V600E
    Thyroid Gland Papillary Carcinoma
    trametinib + dabrafenib
    Sensitive: C1 - Off-label
    BRAF V600E
    Thyroid Gland Papillary Carcinoma
    vemurafenib
    Sensitive: C1 - Off-label
    BRAF mutation
    Thyroid Gland Papillary Carcinoma
    trametinib + dabrafenib
    Sensitive: C2 – Inclusion Criteria
    BRAF mutation
    Thyroid Gland Papillary Carcinoma
    vemurafenib
    Sensitive: C2 – Inclusion Criteria
    BRAF mutation
    Thyroid Gland Papillary Carcinoma
    PLX8394 + cobicistat
    Sensitive: C3 – Early Trials
    BRAF V600
    Thyroid Gland Papillary Carcinoma
    BGB-283
    Sensitive: C3 – Early Trials
    BRAF mutation
    Thyroid Gland Papillary Carcinoma
    dabrafenib
    Sensitive: C3 – Early Trials
    RET fusion
    Thyroid Gland Papillary Carcinoma
    cabozantinib tablet
    Sensitive: C3 – Early Trials
    BRAF V600E
    Thyroid Gland Papillary Carcinoma
    siltuximab
    Sensitive: C4 – Case Studies
    PDGFRB overexpression
    Thyroid Gland Papillary Carcinoma
    larotrectinib
    Sensitive: C4 – Case Studies
    EGFR overexpression
    Thyroid Gland Papillary Carcinoma
    larotrectinib
    Sensitive: C4 – Case Studies
    BRAF V600
    Thyroid Gland Papillary Carcinoma
    dabrafenib + SNR1611
    Sensitive: C4 – Case Studies
    NCOA4-RET fusion
    Thyroid Gland Papillary Carcinoma
    lenvatinib
    Sensitive: C4 – Case Studies
    TPM3-NTRK1 fusion
    Thyroid Gland Papillary Carcinoma
    AB-106
    Sensitive: C4 – Case Studies
    GLI3 overexpression
    Thyroid Gland Papillary Carcinoma
    larotrectinib
    Sensitive: C4 – Case Studies
    GLI2 overexpression
    Thyroid Gland Papillary Carcinoma
    larotrectinib
    Sensitive: C4 – Case Studies
    GLI1 overexpression
    Thyroid Gland Papillary Carcinoma
    larotrectinib
    Sensitive: C4 – Case Studies
    TPM3-NTRK1 fusion
    Thyroid Gland Papillary Carcinoma
    larotrectinib
    Sensitive: C4 – Case Studies
    NTRK1 overexpression
    Thyroid Gland Papillary Carcinoma
    larotrectinib
    Sensitive: C4 – Case Studies
    BRAF V600E + TERT mutation
    Thyroid Gland Papillary Carcinoma
    trametinib + dabrafenib
    Resistant: C4 – Case Studies
    BRAF V600E + TERT mutation
    Thyroid Gland Papillary Carcinoma
    sorafenib
    Resistant: C4 – Case Studies
    NRAS Q61K + BRAF V600E
    Thyroid Gland Papillary Carcinoma
    vemurafenib
    Sensitive: C4 – Case Studies
    PTEN R130del
    Thyroid Gland Papillary Carcinoma
    MK-2206
    Sensitive: D – Preclinical
    BRAF mutation
    Thyroid Gland Papillary Carcinoma
    PP2
    Sensitive: D – Preclinical
    RET-PTC1 rearrangement
    Thyroid Gland Papillary Carcinoma
    MK-2206
    Sensitive: D – Preclinical
    PIK3CA E545K
    Thyroid Gland Papillary Carcinoma
    MK-2206
    Sensitive: D – Preclinical
    RET rearrangement
    Thyroid Gland Papillary Carcinoma
    MK-2206
    Sensitive: D – Preclinical
    RET-PTC1 rearrangement
    Thyroid Gland Papillary Carcinoma
    dasatinib + CI-1040
    Sensitive: D – Preclinical
    RET-PTC1 rearrangement
    Thyroid Gland Papillary Carcinoma
    dasatinib
    Sensitive: D – Preclinical
    RET-PTC1 rearrangement
    Thyroid Gland Papillary Carcinoma
    cabozantinib capsule
    Sensitive: D – Preclinical
    RET-PTC1 rearrangement
    Thyroid Gland Papillary Carcinoma
    CI-1040 + SU6656
    Sensitive: D – Preclinical
    RET-PTC1 rearrangement
    Thyroid Gland Papillary Carcinoma
    CI-1040 + PP2
    Sensitive: D – Preclinical
    RET-PTC1 rearrangement
    Thyroid Gland Papillary Carcinoma
    CI-1040
    Sensitive: D – Preclinical
    RET-PTC1 rearrangement
    Thyroid Gland Papillary Carcinoma
    AZD1480
    Sensitive: D – Preclinical
    RET C634W
    Thyroid Gland Papillary Carcinoma
    AZD1480
    Sensitive: D – Preclinical
    RET M918T
    Thyroid Gland Papillary Carcinoma
    AZD1480
    Sensitive: D – Preclinical
    BRAF V600E
    Thyroid Gland Papillary Carcinoma
    trametinib + dabrafenib + AZD1775
    Sensitive: D – Preclinical